High dose intravenous immunoglobulin (IVIg) in severe refractory rheumatoid arthritis: no evidence for efficacy.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Clinical and Experimental Rheumatology

• Publication date

  1996-11-01

• Fields of study

  Medicine

• Identifiers
  PMID 8978962
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Long term treatment of rheumatoid arthritis with high doses of intravenous immunoglobulins: effects on disease activity and serum cytokines.

  1995cited by this paper
• Intravenous immunoglobulin in the treatment of systemic juvenile rheumatoid arthritis: a randomized placebo controlled trial. Pediatric Rheumatology Collaborative Study Group.

  1994cited by this paper
• Circulating concentrations and production of cytokines and soluble receptors in rheumatoid arthritis patients: effects of a single dose methotrexate.

  1994cited by this paper
• Intravenous immunoglobulin treatment of experimental T cell-mediated autoimmune disease. Upregulation of T cell proliferation and downregulation of tumor necrosis factor alpha secretion.

  1994cited by this paper
• LPS-induced sTNF-receptor release in vivo in a murine model. Investigation of the role of tumor necrosis factor, IL-1, leukemia inhibiting factor, and IFN-gamma.

  1993cited by this paper
• Immunologically active proteins in intravenous immunoglobulin.

  1993cited by this paper
• Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice.

  1993cited by this paper
• High-dose immunoglobulin therapy as an immunomodulatory treatment of rheumatoid arthritis.

  1992cited by this paper
• Immunomodulating therapy of rheumatoid arthritis by high-dose intravenous immunoglobulin

  1989cited by this paper
• Intravenous gamma-globulin therapy in systemic lupus erythematosus and immune complex disease.

  1989cited by this paper
• The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.

  1988cited by this paper
• High-dose intravenous gammaglobulin for myasthenia gravis.

  1984cited by this paper

• Serum immunoglobulin and the threshold of Fc receptor-mediated immune activation

  2023cites this paper
• Mouse Models of Rheumatoid Arthritis for Studies on Immunopathogenesis and Preclinical Testing of Fc Receptor-Targeting Biologics

  2020cites this paper
• Using the K/BxN mouse model of endogenous, chronic, rheumatoid arthritis for the evaluation of potential immunoglobulin-based therapeutic agents, including IVIg and Fc-μTP-L309C, a recombinant IgG1 Fc hexamer

  2019cites this paper
• A field guide to human Fc-gamma receptors genetics, cellular expression and interaction with immunoglobulins

  2017cites this paper
• A field guide to human Fc-gamma receptors: Genetics, cellular expression and interaction with immunoglobulins

  2017cites this paper
• The role of intravenous immunoglobulin in treatment of mucous membrane pemphigoid: A review of literature

  2016cites this paper
• The potential of intravenous immunoglobulins for cancer therapy: a road that is worth taking?

  2016cites this paper
• The role of intravenous immunoglobulins in the treatment of rheumatoid arthritis.

  2015cites this paper
• Quiescent Disease from Rheumatoid Arthritis Patients with Selectively Up-regulated on Dendritic Cells TLR4-Mediated Immune Responses and Is IIb Receptor Dampens g The Inhibitory Fc

  2009cites this paper
• Quiescent Disease from Rheumatoid Arthritis Patients with Selectively Up-regulated on Dendritic Cells TLR4-Mediated Immune Responses and Is IIb Receptor Dampens g The Inhibitory Fc

  2009cites this paper
• Evidence for the Use of Intravenous Immunoglobulins—A Review of the Literature

  2009cites this paper
• The Inhibitory FcγIIb Receptor Dampens TLR4-Mediated Immune Responses and Is Selectively Up-regulated on Dendritic Cells from Rheumatoid Arthritis Patients with Quiescent Disease1

  2009cites this paper
• Le immunoglobuline nella terapia delle malattie reumatiche Intravenous immunoglobulin for rheumatic diseases

  2007cites this paper
• Erfolgreiche Therapie eines Ulcus cruris rheumaticum mit systemischen Immunglobulinen

  2006cites this paper
• Intravenous immunoglobulin treatment in vasculitis and connective tissue disorders

  2006cites this paper
• Fc gamma receptor mediated modulation of dendritic cells as a potential strategy in the battle against rheumatoid arthritis.

  2006cites this paper
• [Successful therapy of a rheumatoid leg ulcer with intravenous immunoglobulins].

  2006cites this paper
• Immunomodulatory Effects of Intravenous Immunoglobulins as a Treatment for Autoimmune Diseases, Cancer, and Recurrent Pregnancy Loss

  2005cites this paper
• Dendritic cells, Fcγ receptors, and Toll-like receptors: potential allies in the battle against rheumatoid arthritis

  2005cites this paper
• Treatment of rheumatoid arthritis with IL-1 inhibitors

  2004cites this paper
• High production of proinflammatory and Th1 cytokines by dendritic cells from patients with rheumatoid arthritis, and down regulation upon FcγR triggering

  2004cites this paper
• High production of proinflammatory and Th1 cytokines by dendritic cells from patients with rheumatoid arthritis, and down regulation upon FcgammaR triggering.

  2004cites this paper
• The role of antibodies in mouse models of rheumatoid arthritis, and relevance to human disease.

  2004cites this paper
• High production of proinflammatory and Th1 cytokines by dendritic cells from patients with rheumatoid arthritis, and down regulation upon Fc c R triggering

  2004cites this paper
• Immunoglobulin for rheumatic diseases in the twenty‐first century: take it or leave it?

  2003cites this paper
• Immunomodulation of autoimmune diseases by high-dose intravenous immunoglobulins

  2001cites this paper
• In vivo modulation of cytokine synthesis by intravenous immunoglobulin

  1999cites this paper
• Management of therapy-resistant rheumatoid arthritis.

  1999cites this paper
• Current rheumatological uses of intravenous immunoglobulin.

  1994cites this paper